Navigation Links
MiStent SES erweist sich im klinischen Umfeld als einzigartig
Date:10/28/2013

MiStent traten in beiden Studien über einen Zeitraum von zwei Jahren keinerlei wahrscheinliche oder eindeutige Stent-Thrombosen auf. Aus den im Zuge der beiden Studien durchgeführten detaillierten angiografischen sowie IVUS- und OCT-Aufnahmen inklusive Überprüfung der Endothelfunktion ging hervor, dass die normale Endothelfunktion im Heilungsprozess mittels eines reinen Metall-Stents bewahrt werden konnte.

Dr. Ormiston erklärte: „MiStent ist das einzige Produkt seiner Klasse, das die Parameter der lokalen Freisetzung von Wirkstoffen zu optimieren vermag, da Wirkstoffe bis zu neun Monate im Körper verbleiben und das Polymer innerhalb von nur drei Monaten absorbiert wird. Da der Wirkstoff dreimal länger als das Polymer bestehen bleibt, sorgt MiStent für eine rasche Unterbindung der durch das Polymer ausgelösten Entzündung, sodass das entzündungshemmende und antirestenotische Medikament sechs Monate länger als das Polymer präsent ist."

Dr. med. Dennis Donohoe, Chief Medical Advisor bei Micell, ergänzte: „Wir sind mit den über einen Zeitraum von zwei Jahren gesammelten klinischen Ergebnissen der Studien DESSOLVE I und II sehr zufrieden. Dies gilt insbesondere für die einzigartige Feststellung, dass die Progression eines späten Lumenverlustes über einen Zeitraum von 18 Monaten ausbleibt, und für die durch detaillierte klinische Aufnahmen belegte herausragende Gewebeheilung."

Die im Zuge der TCT vorgestellten Daten wurden kürzlich auch in einem von Experten begutachteten Artikel behandelt, der in JACC Cardiovascular Interventions unter dem Titel „First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus–Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in
'/>"/>

SOURCE Micell Technologies
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. MiStent SES Shown to be Unique in Clinical Setting
2. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
3. Micell Technologies Receives CE Mark Approval for MiStent SES
4. Pfizer zeichnet die südafrikanischen, klinischen Forschungsstandorte von Synexus INSPIRE Standorte aus - als erste in Afrika
5. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
6. Filtrona Porous Technologies präsentiert neue medizinische Schäume und einzigartige Faserprodukte für saubere Arbeitsumgebungen auf MEDICA / COMPAMED-Messe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... Aug. 3, 2015  Array BioPharma Inc. (NASDAQ: ... fourth quarter and full year of its fiscal ... Squarer, Chief Executive Officer of Array, noted, "Binimetinib and ... are on track for regulatory submissions in 2016. ... melanoma and BRAF-mutant colorectal cancer further validate the ...
(Date:8/3/2015)... Japan and FLORHAM PARK, N.J. ... announced that once-daily naldemedine met its primary and secondary ... the treatment of opioid-induced constipation (OIC) in adult patients ... peripherally acting mu-opioid receptor antagonist (PAMORA). This is the ... primary and key secondary endpoints. Study results ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... ISELIN, N.J., Nov. 12 Pharmos Corporation (Pink Sheets: PARS) today ... September 30, 2009. , Third Quarter Ended September 30, 2009 ... or $0.02 per share, for the third quarter 2009 compared to ... the third quarter 2008. Cash and cash equivalents totaled $1.3 million ...
... , PRINCETON, N.J. and SAN DIEGO, Nov. 12 ... committed to research and product discovery for the ... announced pharmacokinetic data and results from two double-blind, ... The two studies, a single-ascending dose (SAD) ...
Cached Medicine Technology:Pharmos Corporation Reports 2009 Third Quarter Results 2Pharmos Corporation Reports 2009 Third Quarter Results 3Pharmos Corporation Reports 2009 Third Quarter Results 4Pharmos Corporation Reports 2009 Third Quarter Results 5Pharmos Corporation Reports 2009 Third Quarter Results 6Pharmos Corporation Reports 2009 Third Quarter Results 7Pharmos Corporation Reports 2009 Third Quarter Results 8Pharmos Corporation Reports 2009 Third Quarter Results 9Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference 2
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning Labels is pleased to ... that will usher in a new standard of sticker and label-making for the ... meet its twin objectives of quality and quantity without compromising the signature lightning-fast ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
(Date:8/3/2015)... (PRWEB) , ... August 04, 2015 , ... ... HomeCEUConnection.com announced today an extensive line up of live courses for the month ... more live courses individually or by purchasing a Physical Therapy Flex ...
(Date:8/3/2015)... ... 03, 2015 , ... Zeiter’s Septic now performs septic installations ... and operated business, Zeiter’s Septic has been serving the community for over 20 ... because of their continued training and perseverance to provide their customers with new ...
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... men treated with a combination of radiation seed implants ... cured of their disease 15 years// following their treatment, ... Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. ... at the Seattle Prostate Institute. Doctors wanted to look ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... alleviate symptoms of early-stage Parkinson's disease, and may be ... the brain disorder,// researchers said., ,A neupro patch ... to study its effects on 277 people in Canada ... is designed to convey a drug called rotigotine ...
... Parkinson's appear to increase the risk of heart valve disease, ... disorder of the central nervous system that often impairs motor ... that keep blood flowing in the right direction through the ... blood may not move the way it should., ,The ...
... is the final awakening' - Walter Scott// ... the former president of Iraq, Saddam Hussein, was sent to the ... the fact that he slaughtered 148 fellow countrymen, who were Shias, ... put to use in all societies to wipe out political dissent. ...
... Inner city dwellings were thought to be far cleaner and ... say this is not true- inner cities are a haven// ... and TNS analyzed smoking and disease rates and dietary habits ... The analysis revealed that towns such as Merthyr Tydfil in ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
Medicine Products: